Statement of Operations (USD $)
 12 Months Ended 153 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2013
Revenues:      
Research $ 0 $ 0 $ 0
Expenses:      
General and administrative 4,260,363 2,713,149 34,320,507
Research and development 3,253,139 3,392,896 38,531,638
Patent fees 428,203 431,099 2,960,307
Depreciation and amortization 37,133 42,386 720,056
Total Expenses 7,978,838 6,579,530 76,532,508
Loss from Operations (7,978,838) (6,579,530) (76,532,508)
Other Income (Expense)      
Realized loss on marketable securities     (13,301)
Interest income 49,280 21,092 1,491,679
Interest expense     (301,147)
Other income     56,047
Unrealized (loss)/gain on fair value of warrants (1,365,654) 663,876 2,974,327
Unrealized gain on fair value of put feature on common stock     2,315,539
Financing expense (204,212) (332,108) (1,176,343)
Beneficial conversion feature     (1,625,000)
Total Other Income (Expense) (1,520,586) 352,860 3,721,801
Loss Before Provision for Income Taxes (9,499,424) (6,226,670) (72,810,707)
Provision for Income Taxes 0 0 0
Net Loss $ (9,499,424) $ (6,226,670) $ (72,810,707)
Net loss per share, basic and diluted $ (0.07) $ (0.06)  
Weighted average number of shares outstanding, basic and diluted 128,649,303 97,138,233